**5. Conclusions**

In conclusion, our results indicate that the intrinsic migration and differentiation capacity of fetal HSPCs does not alter significantly in PE pregnancies. However, PE is associated with transcriptional and proteomic changes in fetal erythroid cells that may disrupt erythroid maturation, particularly in male fetuses.

**Supplementary Materials:** Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/8/2038/ s1. Reference [109] is cited in the supplementary materials.

**Author Contributions:** Conceptualization, Z.M. and S.R.H.; Investigation and validation, Z.M., E.H., M.F. and A.G.A.; Formal analysis, Z.M., G.E.M., K.H., Á.C.-C., A.G.A.; Project administration, Z.M., G.E.M.; Supervision, L.E., E.M., M.M., J.R.V., M.F. and S.R.H.; Writing—original draft preparation and visualization, Z.M.; All the authors reviewed and revised the manuscript; funding acquisition: M.F., S.R.H.

**Funding:** This project was supported by Erasmus + Program of the European Union (Framework agreemen<sup>t</sup> number: 2013-0040).

**Acknowledgments:** We specifically thank Per Anders Bertilsson (Flow Cytometry Core Facility, Clinical Research Center, Lund University) and Vanessa Brys (Genomics Core, UZ Leuven) for their excellent skillful technical assistance. We appreciate Annika Thorsell and Carina Sihbom's help with the TMT-mass spectrometry (Proteomics Core Facility, Sahlgrenska Academy, University of Gothenburg). We are grateful to the staff at Skåne University Hospital for assisting with sample collection.

**Conflicts of Interest:** S.R.H. holds patent related to diagnosis and treatment of preeclampsia and is co-founder of A1M Pharma and Preelumina Diagnostics (www.a1m.se). All the other authors declare no competing interests.
